Mallinckrodt files NDA for Optimark
Mallinckrodt has filed a new drug application for its Optimark MRI contrast agent, the St. Louis company announced this month. Optimark (Gd-DTPA-BMEA) is an extracellular agent designed for visualizing lesions in the brain, spine, and liver. Mallinckrodt
Mallinckrodt has filed a new drug application for its Optimark MRI contrast agent, the St. Louis company announced this month. Optimark (Gd-DTPA-BMEA) is an extracellular agent designed for visualizing lesions in the brain, spine, and liver. Mallinckrodt developed the product internally.
Optimark's approval will be an important milestone for Mallinckrodt, rounding out its product portfolio and making it easier for the company to win single-source supply deals with large purchasers. Mallinckrodt's product line already includes agents for x-ray, ultrasound, and CT, as well as organ-specific MRI studies, but the firm does not offer contrast media for MRI scans in the central nervous system, which composes the lion's share of MRI studies. Optimark will compete with general-purpose MRI agents such as Schering's Magnevist, Bracco's ProHance, and Nycomed Amersham's Omniscan.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
Can Abbreviated MRI Have an Impact in Differentiating Intraductal Papilloma and Ductal Secretion?
June 3rd 2025For patients with inconclusive ultrasound results, abbreviated breast MRI offers comparable detection of intraductal papilloma as a full breast MRI protocol at significantly reduced times for scan acquisition and interpretation, according to a new study.
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
